NCT01829217View on ClinicalTrials.gov

Sunitinib in Never-Smokers With Lung Adenocarcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

August 31, 2017

Study Completion Date

January 31, 2018

Conditions
Lung Cancer
Interventions
DRUG

Sunitinib

Trial Locations (4)

02214

Massachusetts General Hospital, Boston

02215

Beth Isreal Deaconess Medical Center, Boston

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

Dana-Farber Cancer Institute

OTHER

NCT01829217 - Sunitinib in Never-Smokers With Lung Adenocarcinoma | Biotech Hunter | Biotech Hunter